The use of 3-D dose volume analysis to predict radiation hepatitis

Lawrence, Theodore S.; Kessler, M.L.; Lavigne, M.L.; Lyman, J.T.; Haken, R.K. Ten

doi:10.1016/0360-3016(91)90564-k

Cited by 237 publications

(102 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38,39 Some studies demonstrated that the radiation tolerance of the liver was affected strongly by the irradiated volume of the liver; for instance, the doses associated with a 5% risk of radiation-induced liver disease for irradiation volumes of one-third and two-thirds were 90 Gy and 47 Gy, respectively. 40,41 These findings suggest that high-dose irradiation to the part of the liver that includes HCC may be delivered effectively and safely.…”

Section: Discussionmentioning

confidence: 89%

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Hata

Tokuuye

Sugahara

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDTreatment modalities for patients with hepatocellular carcinoma (HCC) who have portal vein tumor thrombus (PVTT) are limited and controversial; furthermore, the prognosis for these patients is extremely poor. The authors conducted a retrospective review to determine the role of proton beam therapy in the treatment of patients who had HCC with PVTT.METHODSTwelve patients with HCC who had tumor thrombus in the main trunk or major branches of the portal vein (clinical T3–T4N0M0) were treated with proton beam therapy. At the time they received proton beam irradiation, patients ranged in age from 42 years to 80 years (median, 62 years), and their tumors ranged in size from 40 mm to 110 mm (median, 60 mm) in greatest dimension. A total dose of 50–72 gray (Gy) (median, 55 Gy) in 10–22 fractions was delivered to the tumors, including PVTT.RESULTSAll tumors that were treated with proton beam therapy remained controlled at a median follow‐up of 2.3 years (range, 0.3–7.3 years). Among 12 patients, 10 patients had new liver tumors outside the irradiated volume 0.1–2.4 years after proton beam therapy, and 3 patients also had distant metastases; consequently, 8 patients died of disease, and 2 patients were salvaged by further therapies. The remaining two patients were alive with no evidence of disease 4.3 years and 6.4 years after proton beam therapy. The progression‐free survival rates were 67% at 2 years and 24% at 5 years. The median progression‐free survival was 2.3 years. According to the Acute Radiation Morbidity Scoring Criteria (Radiation Therapy Oncology Group), therapy‐related toxicity ≥ Grade 3 was not observed.CONCLUSIONSProton beam therapy for patients with HCC who had PVTT was feasible and effective. It appeared to improve survival and local control significantly for these patients. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 89%

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Hata

Tokuuye

Sugahara

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…39 However, such limitation has been overcome by recent developments in RT technology involving precise delivery of focused highdose on partial volume of the liver. 40 Patients with HCC in terminal stage need full symptomatic palliation for local disease or distant metastasis. The most frequent sites of metastases from HCC are the lungs and lymph nodes, followed by the skeletal system.…”

Section: Role Of Radiotherapy In Terminal Stage Hepatocellular Carcinomamentioning

confidence: 99%

Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma

Kumar

Panda

2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…29 However, the newer techniques of three-dimensional conformal HIR have enabled investigators to deliver higher doses to parts of the liver, without inducing RILD. 30,31 Radiation sensitivity of the liver varies in different species. The rat liver is less sensitive to radiation-induced liver injury than is human liver, as evidenced by our finding that 50 Gy doses in single fractions were tolerated by the Gunn rats, whereas doses exceeding 30-35 Gy are known to cause long-term radiation injury to the human liver.…”

Section: Discussionmentioning

confidence: 99%

A novel strategy for in vivo expansion of transplanted hepatocytes using preparative hepatic irradiation and FasL-induced hepatocellular apoptosis

et al. 2003

View full text Add to dashboard Cite

A strategy for inducing preferential proliferation of the engrafted hepatocytes over host liver cells should markedly increase the benefit of hepatocyte transplantation for the treatment of liver diseases and ex vivo gene therapy. We hypothesized that preparative hepatic irradiation (HIR) to inhibit host hepatocellular regeneration in combination with the mitotic stimulus of host hepatocellular apoptosis should permit repopulation of the liver by transplanted cells. To test this hypothesis, congeneic normal rat hepatocytes were transplanted into UDP-glucuronosyltransferase (UGT1A1)-deficient jaundiced Gunn rats (a model of Crigler-Najjar syndrome type I), following HIR and adenovirus-mediated FasL gene transfer. Progressive repopulation of the liver by engrafted UGT1A1-proficient hepatocytes over 5 months was demonstrated by the appearance of UGT1A1 protein and enzyme activity in the liver, biliary bilirubin glucuronides secretion, and long-term normalization of serum bilirubin levels. This is the first demonstration of massive hepatic repopulation by transplanted cells by HIR and FasL-induced controlled apoptosis of host liver cells.

show abstract

The use of 3-D dose volume analysis to predict radiation hepatitis

Cited by 237 publications

References 0 publications

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus

Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma

A novel strategy for in vivo expansion of transplanted hepatocytes using preparative hepatic irradiation and FasL-induced hepatocellular apoptosis

Contact Info

Product

Resources

About